HDAC6 and cancer: As SPOP is frequently mutated in several cancers, which might lead to a high level of HDAC6 and could alter the sensitivity to HDAC6 specific inhibitors, we envision that our studies may offer a potential novel therapeutic strategy to treat SPOP-mutant cancer patients with HDAC6 selective inhibitors.